Synthink Research Chemicals

Executive Summary

Synthink Research Chemicals is an Indian supplier of high-purity pharmaceutical impurity reference standards, building blocks, and custom synthesis services, serving drug development and regulatory filing needs across oncology, cardiology, CNS, respiratory, and infectious diseases. Founded in 2020 and based in Mumbai, the company leverages a fully equipped research facility to provide well-characterized standards with comprehensive analytical data (NMR, MS, HPLC). Its platform business model addresses the growing demand for quality impurity standards driven by stricter regulatory requirements and increasing generic drug development in emerging markets. With 50-200 employees, Synthink is positioned as a reliable partner for pharma companies seeking cost-effective, timely solutions for method validation and quality control. The company's growth prospects are supported by the expansion of the global pharmaceutical reference standards market, projected to grow at a CAGR of ~7% through 2030, and India's competitive advantage in chemical synthesis. However, as a private, platform-stage company, Synthink faces risks from competition, potential regulatory changes, and customer concentration. Its conviction score reflects a moderate upside potential underpinned by recurring demand and scalability, but limited by its niche focus and lack of proprietary products. Near-term catalysts could include facility expansions, new service offerings, or strategic partnerships that broaden its customer base and accelerate revenue growth.

Upcoming Catalysts (preview)

• Q4 2026Expansion of impurity standards library into new therapeutic areas70% success
• TBDStrategic partnership with a top-20 pharma company for custom synthesis40% success
• Q2 2027ISO 17025 accreditation for analytical testing services80% success